Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	JUN kinase activity	MAPK8 MAPK9	6.98e-05	3	97	2	GO:0004705
GeneOntologyMolecularFunction	ryanodine-sensitive calcium-release channel activity	RYR1 RYR3	1.39e-04	4	97	2	GO:0005219
GeneOntologyMolecularFunction	dynein light intermediate chain binding	DNHD1 RILPL2 DNAH2	3.33e-04	28	97	3	GO:0051959
GeneOntologyMolecularFunction	oleate transmembrane transporter activity	SLC27A6 SLC27A4	3.46e-04	6	97	2	GO:1901480
GeneOntologyMolecularFunction	calcium-induced calcium release activity	RYR1 RYR3	3.46e-04	6	97	2	GO:0048763
GeneOntologyMolecularFunction	microtubule motor activity	DNHD1 CENPE DNAH2 KIF18B	3.75e-04	70	97	4	GO:0003777
GeneOntologyMolecularFunction	intracellularly ligand-gated monoatomic ion channel activity	RYR1 RYR3 CNGB3	5.45e-04	33	97	3	GO:0005217
GeneOntologyMolecularFunction	ATP-dependent activity	DNHD1 SLC27A6 CENPE DNAH2 PSMC6 NAV3 DDX43 KIF18B DNA2 SLC27A4	8.00e-04	614	97	10	GO:0140657
Domain	Myotonic_dystrophy_kinase_coil	CDC42BPG CDC42BPB DMPK	5.41e-07	4	97	3	IPR014930
Domain	Myotonic_dystrophy_kinase_coil	CDC42BPG CDC42BPB DMPK	5.41e-07	4	97	3	PD011252
Domain	DMPK_coil	CDC42BPG CDC42BPB DMPK	5.41e-07	4	97	3	PF08826
Domain	CNH	CDC42BPG VPS39 CDC42BPB	4.74e-05	14	97	3	SM00036
Domain	CNH	CDC42BPG VPS39 CDC42BPB	5.91e-05	15	97	3	PF00780
Domain	CNH	CDC42BPG VPS39 CDC42BPB	5.91e-05	15	97	3	PS50219
Domain	CNH_dom	CDC42BPG VPS39 CDC42BPB	5.91e-05	15	97	3	IPR001180
Domain	Ryanrecept_TM4-6	RYR1 RYR3	7.98e-05	3	97	2	IPR009460
Domain	RyR	RYR1 RYR3	7.98e-05	3	97	2	PF02026
Domain	Ryanodine_rcpt	RYR1 RYR3	7.98e-05	3	97	2	IPR003032
Domain	RR_TM4-6	RYR1 RYR3	7.98e-05	3	97	2	PF06459
Domain	Ryan_recept	RYR1 RYR3	7.98e-05	3	97	2	IPR013333
Domain	PH	CDC42BPG RASA1 RASGRF2 ARHGAP10 GRB7 CDC42BPB PLCG2	1.92e-04	229	97	7	PF00169
Domain	MAPK_JNK	MAPK8 MAPK9	2.64e-04	5	97	2	IPR008351
Domain	RIH_assoc	RYR1 RYR3	3.95e-04	6	97	2	PF08454
Domain	RIH_assoc-dom	RYR1 RYR3	3.95e-04	6	97	2	IPR013662
Domain	RIH_dom	RYR1 RYR3	3.95e-04	6	97	2	IPR000699
Domain	Ins145_P3_rcpt	RYR1 RYR3	3.95e-04	6	97	2	IPR014821
Domain	Ryanodine_recept-rel	RYR1 RYR3	3.95e-04	6	97	2	IPR015925
Domain	-	RYR1 RYR3	3.95e-04	6	97	2	1.25.10.30
Domain	RYDR_ITPR	RYR1 RYR3	3.95e-04	6	97	2	PF01365
Domain	Ins145_P3_rec	RYR1 RYR3	3.95e-04	6	97	2	PF08709
Domain	PH	CDC42BPG RASA1 RASGRF2 ARHGAP10 GRB7 CDC42BPB PLCG2	6.16e-04	278	97	7	SM00233
Domain	PH_DOMAIN	CDC42BPG RASA1 RASGRF2 ARHGAP10 GRB7 CDC42BPB PLCG2	6.29e-04	279	97	7	PS50003
Domain	PH_domain	CDC42BPG RASA1 RASGRF2 ARHGAP10 GRB7 CDC42BPB PLCG2	6.43e-04	280	97	7	IPR001849
Domain	Rho_GTPase_activation_prot	RASA1 ARHGAP10 SH3BP1 ARHGAP35	1.14e-03	88	97	4	IPR008936
Domain	MIR	RYR1 RYR3	1.17e-03	10	97	2	PS50919
Domain	MIR	RYR1 RYR3	1.17e-03	10	97	2	PF02815
Domain	MIR	RYR1 RYR3	1.17e-03	10	97	2	SM00472
Domain	MIR_motif	RYR1 RYR3	1.17e-03	10	97	2	IPR016093
Domain	Pkinase_C	CDC42BPG CDC42BPB DMPK	1.35e-03	42	97	3	PF00433
Domain	PH_dom-like	CDC42BPG RASA1 RASGRF2 ARHGAP10 GRB7 CDC42BPB TYK2 PLCG2	1.69e-03	426	97	8	IPR011993
Domain	MAP_kinase_CS	MAPK8 MAPK9	1.70e-03	12	97	2	IPR003527
Domain	MAPK	MAPK8 MAPK9	1.70e-03	12	97	2	PS01351
Domain	Kinase-like_dom	CDC42BPG DYRK1A ARHGAP35 CDC42BPB MAP3K4 TYK2 MAPK8 DMPK MAPK9	2.03e-03	542	97	9	IPR011009
Domain	Dynein_HC_stalk	DNHD1 DNAH2	2.33e-03	14	97	2	IPR024743
Domain	Dynein_heavy_dom-2	DNHD1 DNAH2	2.33e-03	14	97	2	IPR013602
Domain	DHC_N2	DNHD1 DNAH2	2.33e-03	14	97	2	PF08393
Domain	MT	DNHD1 DNAH2	2.33e-03	14	97	2	PF12777
Domain	Ser/Thr_kinase_AS	CDC42BPG DYRK1A CDC42BPB MAP3K4 MAPK8 DMPK MAPK9	2.59e-03	357	97	7	IPR008271
Domain	SH2	RASA1 GRB7 TYK2 PLCG2	2.59e-03	110	97	4	SM00252
Domain	S_TKc	CDC42BPG DYRK1A CDC42BPB MAP3K4 MAPK8 DMPK MAPK9	2.67e-03	359	97	7	SM00220
Domain	SH2	RASA1 GRB7 TYK2 PLCG2	2.68e-03	111	97	4	PS50001
Domain	DHC_fam	DNHD1 DNAH2	2.68e-03	15	97	2	IPR026983
Domain	Dynein_heavy_dom	DNHD1 DNAH2	2.68e-03	15	97	2	IPR004273
Domain	Dynein_heavy	DNHD1 DNAH2	2.68e-03	15	97	2	PF03028
Domain	PROTEIN_KINASE_ATP	CDC42BPG DYRK1A CDC42BPB MAP3K4 TYK2 MAPK8 DMPK MAPK9	2.68e-03	459	97	8	PS00107
Domain	SH2	RASA1 GRB7 TYK2 PLCG2	2.77e-03	112	97	4	IPR000980
Domain	-	RASA1 GRB7 TYK2 PLCG2	2.77e-03	112	97	4	3.30.505.10
Domain	PROTEIN_KINASE_ST	CDC42BPG DYRK1A CDC42BPB MAP3K4 MAPK8 DMPK MAPK9	2.80e-03	362	97	7	PS00108
Domain	Ion_trans_dom	RYR1 RYR3 KCND2 CNGB3	2.95e-03	114	97	4	IPR005821
Domain	Ion_trans	RYR1 RYR3 KCND2 CNGB3	2.95e-03	114	97	4	PF00520
Domain	AGC-kinase_C	CDC42BPG CDC42BPB DMPK	3.08e-03	56	97	3	IPR000961
Domain	AGC_KINASE_CTER	CDC42BPG CDC42BPB DMPK	3.08e-03	56	97	3	PS51285
Domain	S_TK_X	CDC42BPG CDC42BPB DMPK	3.08e-03	56	97	3	SM00133
Domain	PBD	CDC42BPG CDC42BPB	3.45e-03	17	97	2	PF00786
Domain	AMP-bd_C	SLC27A6 SLC27A4	3.45e-03	17	97	2	IPR025110
Domain	AMP-binding_C	SLC27A6 SLC27A4	3.45e-03	17	97	2	PF13193
Domain	Pkinase	CDC42BPG DYRK1A CDC42BPB MAP3K4 MAPK8 DMPK MAPK9	3.71e-03	381	97	7	PF00069
Domain	Prot_kinase_dom	CDC42BPG DYRK1A CDC42BPB MAP3K4 TYK2 MAPK8 DMPK MAPK9	3.94e-03	489	97	8	IPR000719
Domain	RhoGAP	ARHGAP10 SH3BP1 ARHGAP35	4.11e-03	62	97	3	SM00324
Domain	PROTEIN_KINASE_DOM	CDC42BPG DYRK1A CDC42BPB MAP3K4 TYK2 MAPK8 DMPK MAPK9	4.14e-03	493	97	8	PS50011
Domain	-	CDC42BPG RASA1 RASGRF2 ARHGAP10 GRB7 CDC42BPB PLCG2	4.27e-03	391	97	7	2.30.29.30
Domain	RhoGAP	ARHGAP10 SH3BP1 ARHGAP35	4.30e-03	63	97	3	PF00620
Domain	BAR	ARHGAP10 SH3BP1	4.31e-03	19	97	2	PS51021
Domain	RHOGAP	ARHGAP10 SH3BP1 ARHGAP35	4.50e-03	64	97	3	PS50238
Domain	RhoGAP_dom	ARHGAP10 SH3BP1 ARHGAP35	4.50e-03	64	97	3	IPR000198
Domain	-	ARHGAP10 SH3BP1 ARHGAP35	4.50e-03	64	97	3	1.10.555.10
Domain	CRIB	CDC42BPG CDC42BPB	4.77e-03	20	97	2	PS50108
Domain	USP_CS	USP24 USP9Y USP14	4.90e-03	66	97	3	IPR018200
Pathway	PID_FAK_PATHWAY	RASA1 GRB7 ARHGAP35 MAPK8 MAPK9	1.49e-05	59	75	5	M281
Pubmed	Cytochrome P4502E1, oxidative stress, JNK, and autophagy in acute alcohol-induced fatty liver.	CYP2E1 MAPK8 MAPK9	2.17e-08	3	98	3	22749809
Pubmed	Loss of mitogen-activated protein kinase kinase kinase 4 (MEKK4) results in enhanced apoptosis and defective neural tube development.	MAP3K4 MAPK8 MAPK9	8.66e-08	4	98	3	15731347
Pubmed	MRCKα is activated by caspase cleavage to assemble an apical actin ring for epithelial cell extrusion.	CDC42BPG CDC42BPB DMPK	7.53e-07	7	98	3	29162624
Pubmed	The c-Jun NH2-terminal kinase is essential for epidermal growth factor expression during epidermal morphogenesis.	TP63 MAPK8 MAPK9	2.57e-06	10	98	3	15375216
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	CDC42BPG RASA1 ARHGAP10 KIAA0232 RALGAPB ARHGAP35 CDC42BPB TYK2 USP14 PCNX4 NAT10 BSCL2 GREB1 FBXO21 PLOD1 CNOT1	4.05e-06	1489	98	16	28611215
Pubmed	METTL3 protects METTL14 from STUB1-mediated degradation to maintain m6 A homeostasis.	COL6A3 PSMC6 RYR3 SND1 CCAR2 USH2A STOML2	4.31e-06	231	98	7	36597993
Pubmed	p73 regulates neurodegeneration and phospho-tau accumulation during aging and Alzheimer's disease.	TP63 MAPK8 MAPK9	7.72e-06	14	98	3	18786355
Pubmed	C-Jun N-terminal kinase (JNK) isoforms play differing roles in otitis media.	MAPK8 MAPK9	7.86e-06	2	98	2	25311344
Pubmed	Genetic inhibition or activation of JNK1/2 protects the myocardium from ischemia-reperfusion-induced cell death in vivo.	MAPK8 MAPK9	7.86e-06	2	98	2	16043490
Pubmed	Combined Activities of JNK1 and JNK2 in Hepatocytes Protect Against Toxic Liver Injury.	MAPK8 MAPK9	7.86e-06	2	98	2	26708719
Pubmed	Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance.	MAPK8 MAPK9	7.86e-06	2	98	2	16818881
Pubmed	Suppression of inflammatory cytokine production by carbon monoxide involves the JNK pathway and AP-1.	MAPK8 MAPK9	7.86e-06	2	98	2	12857751
Pubmed	JNK1, but not JNK2, is required in two mechanistically distinct models of inflammatory arthritis.	MAPK8 MAPK9	7.86e-06	2	98	2	21839715
Pubmed	Prevention of steatosis by hepatic JNK1.	MAPK8 MAPK9	7.86e-06	2	98	2	19945406
Pubmed	Hypothermia attenuates ischemia/reperfusion-induced endothelial cell apoptosis via alterations in apoptotic pathways and JNK signaling.	MAPK8 MAPK9	7.86e-06	2	98	2	19596001
Pubmed	Increased JNK in males compared with females in a rodent model of abdominal aortic aneurysm.	MAPK8 MAPK9	7.86e-06	2	98	2	22316675
Pubmed	c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis.	MAPK8 MAPK9	7.86e-06	2	98	2	11435459
Pubmed	The JNKs differentially regulate RNA polymerase III transcription by coordinately modulating the expression of all TFIIIB subunits.	MAPK8 MAPK9	7.86e-06	2	98	2	19620725
Pubmed	Contractile impairment and structural alterations of skeletal muscles from knockout mice lacking type 1 and type 3 ryanodine receptors.	RYR1 RYR3	7.86e-06	2	98	2	9489997
Pubmed	The block of ryanodine receptors selectively inhibits fetal myoblast differentiation.	RYR1 RYR3	7.86e-06	2	98	2	12640042
Pubmed	JNK inhibition reduces apoptosis and neovascularization in a murine model of age-related macular degeneration.	MAPK8 MAPK9	7.86e-06	2	98	2	23341606
Pubmed	Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1.	CYP2E1 MAPK8	7.86e-06	2	98	2	20166895
Pubmed	Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2.	MAPK8 MAPK9	7.86e-06	2	98	2	10559486
Pubmed	JNK regulates muscle remodeling via myostatin/SMAD inhibition.	MAPK8 MAPK9	7.86e-06	2	98	2	30072727
Pubmed	Possible involvement of ryanodine receptor-mediated intracellular calcium release in the effect of corticotropin-releasing factor on adrenocorticotropin secretion.	RYR1 RYR3	7.86e-06	2	98	2	14592949
Pubmed	Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells.	MAPK8 MAPK9	7.86e-06	2	98	2	14724588
Pubmed	Coordination of JNK1 and JNK2 is critical for GADD45alpha induction and its mediated cell apoptosis in arsenite responses.	MAPK8 MAPK9	7.86e-06	2	98	2	16973625
Pubmed	c-Jun N-terminal kinase 2 suppresses pancreatic cancer growth and invasion and is opposed by c-Jun N-terminal kinase 1.	MAPK8 MAPK9	7.86e-06	2	98	2	33526844
Pubmed	Decreased expression of phosphorylated JNK in breast infiltrating ductal carcinoma is associated with a better overall survival.	MAPK8 MAPK9	7.86e-06	2	98	2	16381010
Pubmed	Protective role of c-Jun N-terminal kinase 2 in acetaminophen-induced liver injury.	MAPK8 MAPK9	7.86e-06	2	98	2	18586006
Pubmed	Morphological abnormalities of adrenal gland and hypertrophy of liver in mutant mice lacking ryanodine receptors.	RYR1 RYR3	7.86e-06	2	98	2	9799464
Pubmed	JNK/SAPK Signaling Is Essential for Efficient Reprogramming of Human Fibroblasts to Induced Pluripotent Stem Cells.	MAPK8 MAPK9	7.86e-06	2	98	2	26867034
Pubmed	JNK1 inhibits transcriptional and pro-apoptotic activity of TAp63γ.	TP63 MAPK8	7.86e-06	2	98	2	26519559
Pubmed	Jun N-terminal kinase 1 regulates epithelial-to-mesenchymal transition induced by TGF-beta1.	MAPK8 MAPK9	7.86e-06	2	98	2	18334556
Pubmed	A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis.	MAPK8 MAPK9	7.86e-06	2	98	2	17202416
Pubmed	The role of JNK in the development of hepatocellular carcinoma.	MAPK8 MAPK9	7.86e-06	2	98	2	21406557
Pubmed	JNK1/2 regulates ER-mitochondrial Ca2+ cross-talk during IL-1β-mediated cell death in RINm5F and human primary β-cells.	MAPK8 MAPK9	7.86e-06	2	98	2	23615449
Pubmed	Signal transduction by the JNK group of MAP kinases.	MAPK8 MAPK9	7.86e-06	2	98	2	11057897
Pubmed	Silencing Jnk1 and Jnk2 accelerates basal lipolysis and promotes fatty acid re-esterification in mouse adipocytes.	MAPK8 MAPK9	7.86e-06	2	98	2	18528680
Pubmed	Expression and functional activity of ryanodine receptors (RyRs) during skeletal muscle development.	RYR1 RYR3	7.86e-06	2	98	2	17118445
Pubmed	RyR3 amplifies RyR1-mediated Ca(2+)-induced Ca(2+) release in neonatal mammalian skeletal muscle.	RYR1 RYR3	7.86e-06	2	98	2	11500519
Pubmed	JNK-dependent Stat3 phosphorylation contributes to Akt activation in response to arsenic exposure.	MAPK8 MAPK9	7.86e-06	2	98	2	22696236
Pubmed	Ablation of the spindle assembly checkpoint by a compound targeting Mps1.	MAPK8 MAPK9	7.86e-06	2	98	2	16113653
Pubmed	c-Jun N-terminal kinase 1 is deleterious to the function and survival of murine pancreatic islets.	MAPK8 MAPK9	7.86e-06	2	98	2	18853132
Pubmed	Ultrafine particles from diesel engines induce vascular oxidative stress via JNK activation.	MAPK8 MAPK9	7.86e-06	2	98	2	19154785
Pubmed	Role of the MAPK/cJun NH2-terminal kinase signaling pathway in starvation-induced autophagy.	MAPK8 MAPK9	7.86e-06	2	98	2	29950132
Pubmed	Specific role of JNK in the maintenance of the tumor-initiating capacity of A549 human non-small cell lung cancer cells.	MAPK8 MAPK9	7.86e-06	2	98	2	23912840
Pubmed	JNK is required for maintaining the tumor-initiating cell-like properties of acquired chemoresistant human cancer cells.	MAPK8 MAPK9	7.86e-06	2	98	2	26235742
Pubmed	C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma.	MAPK8 MAPK9	7.86e-06	2	98	2	12538493
Pubmed	Inhibition of Jun NH2-terminal kinases suppresses the growth of experimental head and neck squamous cell carcinoma.	MAPK8 MAPK9	7.86e-06	2	98	2	17908987
Pubmed	c-Jun N-terminal kinase 1/2 activation by tumor necrosis factor-alpha induces insulin resistance in human visceral but not subcutaneous adipocytes: reversal by liver X receptor agonists.	MAPK8 MAPK9	7.86e-06	2	98	2	19567513
Pubmed	Defective antiviral CD8 T-cell response and viral clearance in the absence of c-Jun N-terminal kinases.	MAPK8 MAPK9	7.86e-06	2	98	2	24673683
Pubmed	[Sodium butyrate do not induce the program of premature senescence in transformants with JNK1,2 knockout].	MAPK8 MAPK9	7.86e-06	2	98	2	19140343
Pubmed	Modulation of the response of prostate cancer cell lines to cisplatin treatment using small interfering RNA.	MAPK8 MAPK9	7.86e-06	2	98	2	23900581
Pubmed	Inhibition of c-Jun N-terminal kinase attenuates low shear stress-induced atherogenesis in apolipoprotein E-deficient mice.	MAPK8 MAPK9	7.86e-06	2	98	2	21629969
Pubmed	c-Jun N-terminal protein kinase 1 (JNK1), but not JNK2, is essential for tumor necrosis factor alpha-induced c-Jun kinase activation and apoptosis.	MAPK8 MAPK9	7.86e-06	2	98	2	15572687
Pubmed	Principal mutation hotspot for central core disease and related myopathies in the C-terminal transmembrane region of the RYR1 gene.	RYR1 RYR3	7.86e-06	2	98	2	12565913
Pubmed	Hepatotoxicity mediated by pyrazole (cytochrome P450 2E1) plus tumor necrosis factor alpha treatment occurs in c-Jun N-terminal kinase 2-/- but not in c-Jun N-terminal kinase 1-/- mice.	MAPK8 MAPK9	7.86e-06	2	98	2	21748763
Pubmed	Purinergic (ATP) signaling stimulates JNK1 but not JNK2 MAPK in osteoblast-like cells: contribution of intracellular Ca2+ release, stress activated and L-voltage-dependent calcium influx, PKC and Src kinases.	MAPK8 MAPK9	7.86e-06	2	98	2	18625195
Pubmed	Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway.	MAPK8 MAPK9	7.86e-06	2	98	2	16571730
Pubmed	Functional and morphological features of skeletal muscle from mutant mice lacking both type 1 and type 3 ryanodine receptors.	RYR1 RYR3	7.86e-06	2	98	2	9192302
Pubmed	c-Jun N-terminal kinase 2 promotes enterocyte survival and goblet cell differentiation in the inflamed intestine.	MAPK8 MAPK9	7.86e-06	2	98	2	28098247
Pubmed	Tandem SH2 binding sites mediate the RasGAP-RhoGAP interaction: a conformational mechanism for SH3 domain regulation.	RASA1 ARHGAP35	7.86e-06	2	98	2	9034330
Pubmed	c-Jun N-terminal kinase is upregulated in patients with hypospadias.	MAPK8 MAPK9	7.86e-06	2	98	2	23273084
Pubmed	An initial phase of JNK activation inhibits cell death early in the endoplasmic reticulum stress response.	MAPK8 MAPK9	7.86e-06	2	98	2	27122189
Pubmed	JNK2 up-regulates hypoxia-inducible factors and contributes to hypoxia-induced erythropoiesis and pulmonary hypertension.	MAPK8 MAPK9	7.86e-06	2	98	2	29118187
Pubmed	c-Jun N-terminal kinase activity is required for efficient respiratory syncytial virus production.	MAPK8 MAPK9	7.86e-06	2	98	2	28062184
Pubmed	c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 have distinct roles in CD8(+) T cell activation.	MAPK8 MAPK9	7.86e-06	2	98	2	11927626
Pubmed	c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 signaling pathways have divergent roles in CD8(+) T cell-mediated antiviral immunity.	MAPK8 MAPK9	7.86e-06	2	98	2	11927625
Pubmed	Isolation and partial cloning of ryanodine-sensitive Ca2+ release channel protein isoforms from human myometrial smooth muscle.	RYR1 RYR3	7.86e-06	2	98	2	7556644
Pubmed	Efficient keratinocyte differentiation strictly depends on JNK-induced soluble factors in fibroblasts.	MAPK8 MAPK9	7.86e-06	2	98	2	24335928
Pubmed	Inhibition of cell proliferation and cell cycle progression by specific inhibition of basal JNK activity: evidence that mitotic Bcl-2 phosphorylation is JNK-independent.	MAPK8 MAPK9	7.86e-06	2	98	2	14704147
Pubmed	Differential roles of JNK in ConA/GalN and ConA-induced liver injury in mice.	MAPK8 MAPK9	7.86e-06	2	98	2	18772342
Pubmed	c-Jun NH2-terminal kinase-2 mediates osmotic stress-induced tight junction disruption in the intestinal epithelium.	MAPK8 MAPK9	7.86e-06	2	98	2	20595622
Pubmed	c-Jun NH2-terminal kinase is required for lineage-specific differentiation but not stem cell self-renewal.	MAPK8 MAPK9	7.86e-06	2	98	2	20065035
Pubmed	Ryanodine receptors in muscarinic receptor-mediated bronchoconstriction.	RYR1 RYR3	7.86e-06	2	98	2	15894801
Pubmed	Inhibited neurogenesis in JNK1-deficient embryonic stem cells.	MAPK8 MAPK9	7.86e-06	2	98	2	16314504
Pubmed	JNK1 and 2 play a negative role in reprogramming to pluripotent stem cells by suppressing Klf4 activity.	MAPK8 MAPK9	7.86e-06	2	98	2	24211391
Pubmed	Protective role of c-Jun N-terminal kinase-2 (JNK2) in ibuprofen-induced acute liver injury.	MAPK8 MAPK9	7.86e-06	2	98	2	30264435
Pubmed	Effect of calmodulin on Ca2+-induced Ca2+ release of skeletal muscle from mutant mice expressing either ryanodine receptor type 1 or type 3.	RYR1 RYR3	7.86e-06	2	98	2	9817784
Pubmed	c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D.	MAPK8 MAPK9	7.86e-06	2	98	2	19339050
Pubmed	USP14 promotes colorectal cancer progression by targeting JNK for stabilization.	USP14 MAPK8	7.86e-06	2	98	2	36693850
Pubmed	Absent meibomian glands and cone dystrophy in ADULT syndrome: identification by whole exome sequencing of pathogenic variants in two causal genes TP63 and CNGB3.	TP63 CNGB3	7.86e-06	2	98	2	37158316
Pubmed	Deletion of JNK Enhances Senescence in Joint Tissues and Increases the Severity of Age-Related Osteoarthritis in Mice.	MAPK8 MAPK9	7.86e-06	2	98	2	32418287
Pubmed	Genetic deletion of JNK1 and JNK2 aggravates the DSS-induced colitis in mice.	MAPK8 MAPK9	7.86e-06	2	98	2	17365404
Pubmed	p120RasGAP is a mediator of rho pathway activation and tumorigenicity in the DLD1 colorectal cancer cell line.	RASA1 ARHGAP35	7.86e-06	2	98	2	24465899
Pubmed	Effect of Jun N-terminal kinase 1 and 2 on the replication of Penicillium marneffei in human macrophages.	MAPK8 MAPK9	7.86e-06	2	98	2	25792289
Pubmed	ΔNp63α down-regulates c-Myc modulator MM1 via E3 ligase HERC3 in the regulation of cell senescence.	TP63 HERC3	7.86e-06	2	98	2	29880857
Pubmed	Critical role of c-jun N-terminal protein kinase in promoting mitochondrial dysfunction and acute liver injury.	CYP2E1 MAPK8	7.86e-06	2	98	2	26491845
Pubmed	Loss of inherited genomic imprints in mice leads to severe disruption in placental lipid metabolism.	SLC27A6 HADH SLC27A4	9.63e-06	15	98	3	25662615
Pubmed	Constitutively active mutation of ACVR1 in oral epithelium causes submucous cleft palate in mice.	TP63 MAPK8 MAPK9	9.63e-06	15	98	3	26116174
Pubmed	A Human Tyrosine Phosphatase Interactome Mapped by Proteomic Profiling.	MPO ARHGAP10 PSMC6 IPO4 NCAPG2 TYK2 CCAR2 MAPK8 MAPK9 FBXO21 PLOD1 SLC27A4	1.94e-05	974	98	12	28675297
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	KIAA0232 RALGAPB MAP3K4 NAV3 CCAR2 CHPF2 HERC3 SEZ6L	2.06e-05	407	98	8	12693553
Pubmed	Oppositional regulation of Noxa by JNK1 and JNK2 during apoptosis induced by proteasomal inhibitors.	MAPK8 MAPK9	2.35e-05	3	98	2	23593480
Pubmed	JNK Isoforms Are Involved in the Control of Adult Hippocampal Neurogenesis in Mice, Both in Physiological Conditions and in an Experimental Model of Temporal Lobe Epilepsy.	MAPK8 MAPK9	2.35e-05	3	98	2	30685843
Pubmed	Overexpression or ablation of JNK in skeletal muscle has no effect on glycogen synthase activity.	MAPK8 MAPK9	2.35e-05	3	98	2	15013949
Pubmed	Arrestin-3 binds c-Jun N-terminal kinase 1 (JNK1) and JNK2 and facilitates the activation of these ubiquitous JNK isoforms in cells via scaffolding.	MAPK8 MAPK9	2.35e-05	3	98	2	24257757
Pubmed	MEK kinase 1 activity is required for definitive erythropoiesis in the mouse fetal liver.	MAPK8 MAPK9	2.35e-05	3	98	2	16081685
Pubmed	Inhibition of C-jun N-terminal kinase improves insulin sensitivity but worsens albuminuria in experimental diabetes.	MAPK8 MAPK9	2.35e-05	3	98	2	18971923
Pubmed	Type 1 and type 3 ryanodine receptors are selectively involved in muscarinic antinociception in mice: an antisense study.	RYR1 RYR3	2.35e-05	3	98	2	18403125
GeneFamily	Ryanodine receptors\|Protein phosphatase 1 regulatory subunits	RYR1 RYR3	2.92e-05	3	57	2	287
GeneFamily	Rho GTPase activating proteins\|BCH domain containing	ARHGAP10 SH3BP1 ARHGAP35	5.24e-04	50	57	3	721
GeneFamily	Ubiquitin specific peptidases	USP24 USP9Y USP14	7.31e-04	56	57	3	366
GeneFamily	Mitogen-activated protein kinases	MAPK8 MAPK9	7.45e-04	13	57	2	651
GeneFamily	Beta 3-glycosyltransferases	B3GALNT1 CHPF2	2.58e-03	24	57	2	426
GeneFamily	Acyl-CoA synthetase family	SLC27A6 SLC27A4	3.02e-03	26	57	2	40
GeneFamily	SH2 domain containing	RASA1 GRB7 PLCG2	3.98e-03	101	57	3	741
GeneFamily	Pleckstrin homology domain containing\|Rho guanine nucleotide exchange factors\|C2 domain containing	CDC42BPG RASA1 RASGRF2 GRB7	4.04e-03	206	57	4	682
GeneFamily	Kinesins\|Pleckstrin homology domain containing	CENPE KIF18B	9.25e-03	46	57	2	622
ToppCell	saliva-Mild-Moderate_progression_d12-25-Myeloid-Granulocytic-Neutrophil-Neu_c4-RSAD2\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	VPS39 MTERF2 EDEM2 OR2V2 CDH4	2.46e-05	156	98	5	f5889a6899904dfb7f596600b3a76857cf9d5378
ToppCell	COVID-19-kidney-Technical/muscle_(Mes)\|kidney / Disease (COVID-19 only), tissue and cell type	RYR1 KCND2 NAV3 USH2A CDH4	2.70e-05	159	98	5	5335cbcdeaf2bbd0268bbfe0e45c8c0d288e640d
ToppCell	facs-Pancreas-Exocrine-18m-Hematologic-nan\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CYP11A1 SH3BP1 PIK3R6 PLCG2 DNA2	2.86e-05	161	98	5	16f77e7a5444d2f2b210362816cd7a07b9b42af6
ToppCell	facs-Pancreas-Exocrine-18m-Hematologic\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CYP11A1 SH3BP1 PIK3R6 PLCG2 DNA2	2.86e-05	161	98	5	f5821f551cf5c64c9f75cdb723492c87aac1ece0
ToppCell	facs-Pancreas-Exocrine-18m-Hematologic-leukocyte\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CYP11A1 SH3BP1 PIK3R6 PLCG2 DNA2	2.86e-05	161	98	5	58a32a1033f379579697bda1bbf047a088e4a34f
ToppCell	Transplant_Alveoli_and_parenchyma-Epithelial-Basal_2\|Epithelial / Tissue, Lineage and Cell class of Lung Cells from 10X	RYR1 ATRIP PIK3R6 TP63 SEZ6L	3.04e-05	163	98	5	f21951e63188eb0c04675a8f81a0da495c26c007
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	CENPE KCTD19 NCAPG2 KIF18B DNA2	3.41e-05	167	98	5	50c29ea660bf07b890e4ac1a1985d0761d863dee
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_G2M\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	CENPE KCTD19 NCAPG2 KIF18B DNA2	3.51e-05	168	98	5	d35944fd9fea9934ce1e76b2b35d48e2300cca61
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_G2M\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	CENPE KCTD19 NCAPG2 KIF18B DNA2	3.61e-05	169	98	5	b253a4a50c06d36228fcd5d856c57202cbac158f
ToppCell	COVID-19-kidney-Epi_(Mes)\|kidney / Disease (COVID-19 only), tissue and cell type	ARHGAP10 TMEM151B FRY CFAP54 TP63	4.75e-05	179	98	5	e7c9dc63f03d3f3746b51a7e3c8393089e2ceb7d
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell_cycling\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	CENPE KCTD19 NCAPG2 KIF18B DNA2	4.87e-05	180	98	5	401df9cddcbca1eb8f0d2687bcacd98e95dc1493
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell-parietal_epithelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ARHGAP10 FRY CFAP54 TP63 NAV3	5.00e-05	181	98	5	5f2d3a08577c440c944778d07aa993c6e7873f3d
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell-parietal_epithelial_cell-Parietal_Epithelial_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ARHGAP10 FRY CFAP54 TP63 NAV3	5.00e-05	181	98	5	c7c5f7d4c397b4613c772413a0a679377efffff3
ToppCell	droplet-Lung-nan-18m-Mesenchymal-pulmonary_interstitial_fibroblast\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	B3GALNT1 CYP2E1 CNGB3 GREB1 CDH4	5.69e-05	186	98	5	b58db5abdd3e9f0214b198c3cbd09b0b3c321eab
ToppCell	droplet-Lung-nan-18m-Mesenchymal-Myofibroblast\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	B3GALNT1 CYP2E1 CNGB3 GREB1 CDH4	5.69e-05	186	98	5	cd6502bbf9dce318fdbb4965d49df8951e5f795c
ToppCell	droplet-Lung-18m-Mesenchymal-myofibroblast-myofibroblast_cell-pulmonary_interstitial_myofibroblast\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	B3GALNT1 CYP2E1 CNGB3 GREB1 CDH4	5.84e-05	187	98	5	8bd635abdee5d5a12a3f7bf74eab4282e8e40741
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Immune-Myeloid-Macrophage_Dendritic-Cycling_Mononuclear_Phagocyte\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	CENPE NCAPG2 RYR1 TGM7 KIF18B	5.84e-05	187	98	5	73931a5ea73799095daff100b5f18853c57c74dc
ToppCell	droplet-Lung-18m-Mesenchymal-myofibroblast-myofibroblast_cell\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	B3GALNT1 CYP2E1 CNGB3 GREB1 CDH4	5.84e-05	187	98	5	3cb8cd7f7a4306ff74d1f7f9964014008ec1c6a0
ToppCell	droplet-Marrow-nan-21m-Lymphocytic-nan\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MPO CYP11A1 SND1 EDEM2 PRODH	5.99e-05	188	98	5	7e27e49ec1eb02fb74c86ec2ccb84751bc778b21
ToppCell	droplet-Marrow-nan-21m-Lymphocytic\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MPO CYP11A1 SND1 EDEM2 PRODH	5.99e-05	188	98	5	4b14c3ad80507245564d5be96d33fd9361f67dd0
ToppCell	Control-Fibroblasts-Adventitial_FB\|Control / group, cell type (main and fine annotations)	COL6A3 ARHGAP10 KCND2 NAV3 GREB1	5.99e-05	188	98	5	706a26c372add839d947749f0521a0e1f5c9b0ec
ToppCell	3'_v3-GI_small-bowel-Lymphocytic_T_CD4/8-lo-Cycling_T\|GI_small-bowel / Manually curated celltypes from each tissue	MPO CENPE NCAPG2 KIF18B DNA2	6.45e-05	191	98	5	e642fa7395c05fb53324c9d46bbc52f89fc9673f
ToppCell	droplet-Tongue-Unstain-18m-Epithelial-parabasal\|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ELOVL1 RYR3 ASL DMPK LYG1	6.61e-05	192	98	5	c7185fbc56ffd4c62db47fc240b3207ef65db40e
ToppCell	severe-low-quality_cells\|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	USP24 USP9Y MAP3K4 PLCG2 BRWD1	6.78e-05	193	98	5	9337bc93e3904c7fc7c93c328518bcd6453b1e8c
ToppCell	PBMC-Severe-Myeloid-Neutrophil-immature_Neutrophil-Neu_4\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	MPO CENPE MBOAT2 NCAPG2 PLCG2	6.78e-05	193	98	5	ccab6a0c76f574ef7e1d6d5f1e620376daf21bbf
ToppCell	PBMC-Severe-Myeloid-Neutrophil-immature_Neutrophil-Neu_4\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	MPO CENPE MBOAT2 NCAPG2 PLCG2	6.95e-05	194	98	5	23318a1b55895b5166c6151f488a94a09b4627ff
ToppCell	severe-unassigned\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	MPO CENPE MBOAT2 NCAPG2 PLCG2	7.47e-05	197	98	5	70704b149b2820b8601d2495b7cd9cbe91eda262
Drug	Clorocruoro Hem	MPO CHRNA9 RYR1 RYR3 PLCG2 MAPK8 DMPK MAPK9	5.58e-08	123	97	8	CID003518809
Drug	lysosphingomyelin	ENPP7 RYR1 RYR3 MAP3K4 PLCG2 MAPK8 MAPK9	5.61e-06	160	97	7	CID000005263
Drug	M3/M4	CHRNA9 CYP2E1 RYR1 RYR3	1.02e-05	32	97	4	CID000486507
Drug	Wen-pi-tang-Hab-Wu-ling-san	MPO MAPK8 MAPK9	1.21e-05	11	97	3	ctd:C521629
Drug	M-HT	MPO RASA1 MAPK8 MAPK9 PLOD1	1.23e-05	70	97	5	CID000001136
Drug	Dicumarol	CYP2E1 TP63 MAPK8 MAPK9	1.46e-05	35	97	4	ctd:D001728
Drug	Tetracaine	RYR1 MAPK8 MAPK9	1.60e-05	12	97	3	ctd:D013748
Drug	5'-adenylyl (beta,gamma-methylene)diphosphonate	RYR1 RYR3	1.80e-05	2	97	2	ctd:C005147
Drug	NSC311040	RASGRF2 ARHGAP35 USP9Y MAPK8	1.84e-05	37	97	4	CID000329293
Drug	Bumetanide [28395-03-1]; Down 200; 11uM; MCF7; HT_HG-U133A	SLC27A6 ARHGAP10 VPS39 OGFR GRB7 GREB1 DMPK	2.17e-05	197	97	7	7440_DN
Drug	DiBP	CYP11A1 DYRK1A DMPK	4.88e-05	17	97	3	CID000006782
Drug	cis-diammineplatinum(II	RYR1 RYR3	5.37e-05	3	97	2	CID000159790
Drug	2-hydroxyheptanoic acid	RYR1 RYR3	5.37e-05	3	97	2	CID002750949
Drug	2,6-xylidine	MPO CYP2E1	5.37e-05	3	97	2	ctd:C007766
Drug	8N3-cADPR	RYR1 RYR3	5.37e-05	3	97	2	CID000127713
Drug	aminodantrolene	RYR1 RYR3	5.37e-05	3	97	2	CID009570289
Drug	benzothiazol-2-ylacetonitrile	MAPK8 MAPK9	5.37e-05	3	97	2	CID000342465
Drug	CGC 11093	MAPK8 MAPK9	5.37e-05	3	97	2	ctd:C515676
Drug	2-hydroxycarbazole	RYR1 RYR3	5.37e-05	3	97	2	CID000093551
Drug	1,1'-diheptyl-4,4'-bipyridinium	RYR1 RYR3	5.37e-05	3	97	2	CID000080262
Drug	flubendiamide	RYR1 RYR3	5.37e-05	3	97	2	CID011193251
Drug	Ryanodyl 3-(pyridine-3-carboxylate	RYR1 RYR3	5.37e-05	3	97	2	CID005748312
Drug	Eicosapentaenoic Acid	CYP2E1 SLC22A5 MAPK8 MAPK9 SLC27A4	5.69e-05	96	97	5	ctd:D015118
Drug	1,3-dichloro-2-propanol	CYP11A1 MAPK8 MAPK9	6.91e-05	19	97	3	ctd:C033489
Disease	azoospermia (implicated_via_orthology)	CDC42BPG ESRRB CDC42BPB BSCL2	1.82e-06	27	97	4	DOID:14227 (implicated_via_orthology)
Disease	Conventional (Clear Cell) Renal Cell Carcinoma	DNHD1 GRB7 ASB15 RYR1 NAV3 MAPK8	9.76e-06	148	97	6	C0279702
Disease	congenital myopathy 1A (implicated_via_orthology)	RYR1 RYR3	3.20e-05	3	97	2	DOID:3529 (implicated_via_orthology)
Disease	malignant hyperthermia (implicated_via_orthology)	RYR1 RYR3	3.20e-05	3	97	2	DOID:8545 (implicated_via_orthology)
Disease	Seckel syndrome	CENPE ATRIP DNA2	5.07e-05	22	97	3	C0265202
Disease	leucine measurement, amino acid measurement	NAV3 PRODH	6.39e-05	4	97	2	EFO_0005134, EFO_0009770
Disease	Papillary Renal Cell Carcinoma	DNHD1 GRB7 ASB15 RYR1 NAV3	6.65e-05	128	97	5	C1306837
Disease	Renal Cell Carcinoma	DNHD1 GRB7 ASB15 RYR1 NAV3	6.65e-05	128	97	5	C0007134
Disease	Sarcomatoid Renal Cell Carcinoma	DNHD1 GRB7 ASB15 RYR1 NAV3	6.65e-05	128	97	5	C1266043
Disease	Chromophobe Renal Cell Carcinoma	DNHD1 GRB7 ASB15 RYR1 NAV3	6.65e-05	128	97	5	C1266042
Disease	Collecting Duct Carcinoma of the Kidney	DNHD1 GRB7 ASB15 RYR1 NAV3	6.65e-05	128	97	5	C1266044
Disease	Cholestasis, Extrahepatic	MPO MAPK8 MAPK9	1.59e-04	32	97	3	C0005398
Disease	Seckel syndrome (implicated_via_orthology)	ATRIP DNA2	2.22e-04	7	97	2	DOID:0050569 (implicated_via_orthology)
Disease	peripheral vascular disease	KIAA1549L CSTPP1	2.22e-04	7	97	2	EFO_0003875
Disease	serum IgG glycosylation measurement	KIAA0232 DYRK1A FRY SLC22A5 CHPF2 PLCG2 USH2A LYG1	3.36e-04	523	97	8	EFO_0005193
Disease	childhood gender nonconformity	KIAA1549L SND1 FGF20	3.86e-04	43	97	3	EFO_0020103
Disease	Precancerous Conditions	MPO HADH MAPK8 MAPK9	4.85e-04	110	97	4	C0032927
Disease	Condition, Preneoplastic	MPO HADH MAPK8 MAPK9	4.85e-04	110	97	4	C0282313
Disease	amino acid metabolic disorder (is_implicated_in)	ASL PRODH	5.77e-04	11	97	2	DOID:9252 (is_implicated_in)
Disease	cerebral cavernous malformation (implicated_via_orthology)	CDC42BPG CDC42BPB	5.77e-04	11	97	2	DOID:0060669 (implicated_via_orthology)
Disease	Trigeminal Neuralgia	MAPK8 MAPK9	6.91e-04	12	97	2	C0040997
Disease	Secondary Trigeminal Neuralgia	MAPK8 MAPK9	6.91e-04	12	97	2	C0393787
Disease	Trigeminal Neuralgia, Idiopathic	MAPK8 MAPK9	6.91e-04	12	97	2	C0393786
Disease	Oligospermia	BSCL2 BRWD1	6.91e-04	12	97	2	C0028960
Disease	IGFBP-3 measurement	ATRIP GREB1 CDH4	7.56e-04	54	97	3	EFO_0004626
Disease	caudal middle frontal gyrus volume measurement	FRY PCNX4	1.58e-03	18	97	2	EFO_0010290
Disease	Chronic myeloproliferative disorder	CENPE ATRIP	1.76e-03	19	97	2	C1292778
Disease	Lung Neoplasms	MPO CYP2E1 GRB7 SND1 TP63	1.85e-03	265	97	5	C0024121
Disease	Malignant neoplasm of lung	MPO CYP2E1 GRB7 SND1 TP63	1.88e-03	266	97	5	C0242379
Disease	alpha-tocopherol measurement	DYRK1A USH2A	1.96e-03	20	97	2	EFO_0007898
Disease	Morbilliform Drug Reaction	MPO CYP2E1	2.59e-03	23	97	2	C0406537
Disease	Drug Eruptions	MPO CYP2E1	2.59e-03	23	97	2	C0011609
Disease	phosphatidylethanolamine measurement	SLC27A6 RYR3 PLCG2 USH2A	2.59e-03	173	97	4	EFO_0010228
Disease	response to anticonvulsant	COL6A3 SLC27A6 NAV3	2.80e-03	85	97	3	GO_0036277
Disease	Reperfusion Injury	MPO MAPK8 MAPK9	3.19e-03	89	97	3	C0035126

Protein segments in the cluster

Peptide	Gene	Start	Entry
DFGYRVYKMLLSLPE	CCAR2	551	Q8N163
VLPFYLGAELLIDML	CFAP54	1676	Q96N23
YTYEPRDLPLLIENM	AGR3	141	Q8TD06
YLRELPEPLMTFDLY	SH3BP1	351	Q9Y3L3
RVTRVLIDYMDYVPL	ASB15	496	Q8WXK1
VPLIGKYYIATMALI	CHRNA9	296	Q9UGM1
ILSALMASLPYEYRL	DNHD1	2156	Q96M86
FYRSPEVLLGMPYDL	DYRK1A	326	Q13627
FYLTLEDMLYAPLVL	CAMSAP1	301	Q5T5Y3
MASEILPPTLRYIYG	RASA1	861	P20936
TTLRYGLLILMKYPE	CYP2E1	306	P05181
LYTMALGLLVKYPDS	KCTD19	286	Q17RG1
LVMDYYAGGDLLTLL	CDC42BPG	146	Q6DT37
QYLRSLPEPLMTYEL	ARHGAP10	461	A1A4S6
QLLRDSLDLYLAMYP	FBXO21	406	O94952
VVTRYYRAPEVILGM	MAPK9	186	P45984
LAVRRMPSLLEYLSY	MBOAT2	166	Q6ZWT7
PISEEMQLLLTVYYL	GREB1	431	Q4ZG55
RLLVPYLMEAIRLYE	HADH	221	Q16836
YYITLTIPLAMAILR	HERC3	521	Q15034
PDMLATDLAYYLVRK	ASL	366	P04424
LGYIMSRDLVPRIYE	B3GALNT1	241	O75752
GYPLRPELIESAMYL	EDEM2	366	Q9BV94
DTYEIIPLMRPLYIF	PCNX4	206	Q63HM2
GIDAMIYTRYVLSLL	KIAA0232	51	Q92628
VVTRYYRAPEVILGM	MAPK8	186	P45983
SEGLLLGLMAYDRYV	OR2V1	111	Q8NHB1
SEGLLLGLMAYDRYV	OR2V2	111	Q96R30
GAMVQIITYRDYLPL	MPO	451	P05164
VPYILEAVREGLQMY	NAV3	2266	Q8IVL0
PALVETYSRLLVYME	MED23	561	Q9ULK4
DVVAILPYYIGLVMT	KCND2	266	Q9NZV8
MVRAGLLALEFYTPE	DPP3	546	Q9NY33
LVYLPAVVIEMLGVY	KIAA1549L	891	Q6ZVL6
LRYPVTPELLERYNM	PLCG2	731	P16885
LVMDYYVGGDLLTLL	CDC42BPB	151	Q9Y5S2
PGIMYLTTVELYRRL	KIF18B	126	Q86Y91
LVMEYYVGGDLLTLL	DMPK	146	Q09013
LILPSEEEGRLYFSM	GRB7	481	Q14451
LFLPYDLKRLEMYSR	NAT10	816	Q9H0A0
LLEYIAPMTEKLYPG	PLOD1	616	Q02809
LLYYSVPVLEERMQG	MTERF2	291	Q49AM1
LYLPVRGRETYEMLL	TP63	401	Q9H3D4
MLSPERLALPDYEYL	CSTPP1	1	Q9H6J7
MYDRPLRLNLLDLDY	COL6A3	2001	P12111
LRILYLEAGMYDVPI	CDH4	676	P55283
LYMEIRARLLPVYEL	ADA2	241	Q9NZK5
RYLVNDLVLRDYMIP	CYP11A1	396	P05108
LTYVYFVLSLGPRIM	ELOVL1	36	Q9BW60
VAYPTDLYTIRMRLV	BRWD1	1201	Q9NSI6
RLAEIDMPYLLKYQP	LYG1	56	Q8N1E2
VSGPYIVYMLQDLDI	BRMS1L	206	Q5PSV4
PLLQVIYSLLSYMDL	FRY	2241	Q5TBA9
LLLLLYMYITSRPDR	ATRIP	631	Q8WXE1
PMRLLALDYGADIVY	DUS2	26	Q9NX74
MEILILGIVYRSLPY	ESRRB	281	O95718
RVTPLLMYSDLGYVI	ENPP7	326	Q6UWV6
MYGQPYRVTLELELP	BSCL2	101	Q96G97
YLILYPDMLISGTSI	DNA2	116	P51530
RAMELYGRLYRVVEP	DNAH2	3201	Q9P225
YDRFLPYILMGSLTI	SLC22A5	486	O76082
EYFRPYLGRIEIMGA	RYR1	4171	P21817
SYSREVMPLLLAYLK	IPO4	431	Q8TEX9
YLKEPMIVYVGTLDL	DDX43	441	Q9NXZ2
PDREFLLRVSYMEIY	CENPE	121	Q02224
VYDISYLLGRELMAL	RILPL2	41	Q969X0
YELMLGFYGIRLEDR	OGFR	171	Q9NZT2
RIMELLEYIEALYPS	MAP3K4	356	Q9Y6R4
DPERVPELYKDLLMY	FGF20	196	Q9NP95
PAELNGIIIRYELYM	USH2A	1266	O75445
PRKISGILERYVLYM	USH2A	2166	O75445
LYKRLYLPGESLTFM	SEZ6L	886	Q9BYH1
PLAFLLMLYAVYLVE	TMEM151B	116	Q8IW70
VPYLGMYLTDLAFIE	RASGRF2	1151	O14827
DPFILDVITYYIRMG	PIK3R6	516	Q5UE93
YGPVMEVLPYLSRRA	PRODH	551	O43272
LLLPDYYLVTVMLSG	SND1	211	Q7KZF4
VALIYVERRLLTPMY	OR5K4	46	A6NMS3
YVIDGKMYELSLRPI	ARHGAP35	626	Q9NRY4
QGVEEMLYRLYKPIL	NCAPG2	321	Q86XI2
FDPARGMEYTLDLLL	CHPF2	436	Q9P2E5
DIIYLYDMLFIQPRL	CNGB3	261	Q9NQW8
VTYMALGLALRYVLE	CNOT1	926	A5YKK6
YAPLLDAMVRLAYAL	SNX20	266	Q7Z614
LLYDGFPMDDLISLL	STAG3	206	Q9UJ98
LTGDVLVMDELGYLY	SLC27A4	486	Q6P1M0
VLNYFEPYLGRIEIM	RYR3	4021	Q15413
IDGVLYLRIMDPYKA	STOML2	101	Q9UJZ1
YLTEVVYALLMPAGV	USP9Y	1091	O00507
EEILPAYLSRFYMLL	RALGAPB	531	Q86X10
RILSIMYYAREPGKI	TRMT6	166	Q9UJA5
PYLLEVMFALRELTG	USP24	2396	Q9UPU5
TIMRYLPREVDPLVY	PSMC6	106	P62333
YVLLTRELYDQIMLG	SLC27A6	601	Q9Y2P4
YLPSEILLQEYIMRD	TGM7	151	Q96PF1
YVLLYGPRRVEIMEE	USP14	476	P54578
LVMEYVPLGSLRDYL	TYK2	976	P29597
MFLEISSYYDPGRLI	VPS39	666	Q96JC1
DVYLSLLRMYLSPPS	VPS39	736	Q96JC1
LEMYRLAQVYGLPDL	KLHL42	131	Q9P2K6